Danaher Corporation announced its first-quarter 2025 results, reporting that revenue, earnings, and cash flow surpassed company expectations. The non-GAAP core revenue for the quarter grew in the low-single digits year-over-year.
Key drivers of this performance included continued momentum in the bioprocessing business and better-than-expected respiratory demand within its molecular diagnostics segment. Adjusted diluted net earnings per common share for the quarter were $1.88, significantly above analyst consensus.
For the second quarter of 2025, Danaher projects non-GAAP core revenue to grow in the low-single digits. The company maintained its full-year 2025 expectation for non-GAAP core revenue growth of approximately 3% and initiated full-year adjusted diluted net EPS guidance in the range of $7.60 to $7.75.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.